COMMUNIQUÉS West-GlobeNewswire
-
Salarius Pharmaceuticals to Collaborate with Texas Biomedical Research Institute on Avian Flu Study
01/12/2025 -
Daré Bioscience Announces Return of Rights to Ovaprene®; Phase 3 Program Ongoing; Positive Interim Data and Grant Funding Position Asset for Value-Maximization
01/12/2025 -
Catheter Precision Announces Launch of LockeT in Switzerland
01/12/2025 -
Sutro Biopharma Announces 1-for-10 Reverse Stock Split
01/12/2025 -
BioNexus Gene Lab Corp. (Nasdaq: BGLC) and Fidelion Diagnostics Execute Exclusive Southeast Asia License for VitaGuard™ MRD Platform as Part of Strategic Alliance with Tongshu Gene
01/12/2025 -
Tectonic Therapeutic to Participate in December Investor Conferences
01/12/2025 -
ORIC® Pharmaceuticals Announces Enozertinib (ORIC-114) Poster Presentation in HER2 exon 20 NSCLC at the ESMO Asia Congress 2025
01/12/2025 -
Altimmune Announces CEO Transition and Succession Plan
01/12/2025 -
Biogen and Stoke Therapeutics Announce Presentations at the 2025 American Epilepsy Society Annual Meeting
01/12/2025 -
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
01/12/2025 -
Plus Therapeutics to Present ReSPECT Phase 1 Dose Escalation Study Results for Leptomeningeal Metastases at the 2025 San Antonio Breast Cancer Symposium
01/12/2025 -
Juniper Biosciences Raises Oversubscribed and Upsized $40 Million Seed Financing to Fund Development of Its Innovative Pipeline
01/12/2025 -
New Hope for People Living with a Disease Once Deemed Untreatable: Belite Bio Announces Positive Topline Results from the Pivotal Global, Phase 3 DRAGON Trial of Tinlarebant in Adolescents with Stargardt Disease
01/12/2025 -
DeepHealth Launches Breast Suite, Elevating Breast Cancer Detection, Risk Stratification and Workflow
01/12/2025 -
Burning Rock Announces 2025 Annual General Meeting to be Held on December 23, 2025
01/12/2025 -
Rakovina Therapeutics Announces Three-Month Q3 ended September 30, 2025 Financial Results and Provides Corporate Update
01/12/2025 -
NRG Therapeutics Announces Further Expansion with the Appointment of Paul Thompson as Chief Development Officer
01/12/2025 -
Clue Unveils Our Year In Cycles: A Candid Look at How We Bled, Felt, Loved and Lived in 2025
01/12/2025 -
Clue Unveils Our Year In Cycles: A Candid Look at How We Bled, Felt, Loved and Lived in 2025
01/12/2025
Pages